Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2003
09/18/2003US20030175745 Peptides with growth inhibitory action
09/18/2003US20030175711 Comprises ordered and repetitive antigen or antigenic determinant array for developing vaccines for treatment of infectious diseases, allergies and cancer; microarrays
09/18/2003US20030175685 Using amino acid sequences to control apoptosis and prevent or treat cancer and viral infections
09/18/2003US20030175679 Detecting modulators of ubiquitin conjugating enzyme complex formation; drug screening
09/18/2003US20030175374 Oxidation resistance; anticancer agents, antiinflammatory agents; sunscreen agents
09/18/2003US20030175370 Dry mixture of carbohydrates and drugs; wound healing agents
09/18/2003US20030175356 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma
09/18/2003US20030175313 Preparation of sterile stabilized nanodispersions
09/18/2003US20030175301 Rotavirus pseudoviral particles and use thereof for vectorizing proteins of nucleic acids
09/18/2003US20030175297 Cancer vaccines
09/18/2003US20030175290 Molecular antigen array
09/18/2003US20030175289 TIE ligands
09/18/2003US20030175288 Polypeptides used for induction of cytotoxic T lymphocytes or activation of human leukocyte antigens (HLA), administered as anticarcinogenic vaccines; immunology
09/18/2003US20030175285 Major histocompatibility complex ligands, comprising proteins, peptides, epitopes, polypeptides, mimetics or lipopeptides, used as vaccines
09/18/2003US20030175281 Monoclonal antibodies that preferntially bind to proteins having cytolysis and immunogenic activity
09/18/2003US20030175280 Antagonists to chaperonin 10
09/18/2003US20030175279 Diagnosing and prophylaxis of tumors, endometriosis and fibroids, by administering Endometrial Steroid Binding Protein II (ESBPII) antagonists, then analyzing the polypeptide concentration in cells, tissues or fluids
09/18/2003US20030175276 Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents
09/18/2003US20030175274 Polynucleotides codes for antibodies having amino acid sequences selected from complementary determining regions of variable peptides or single chain fragments, used as anticarcinogenic agents
09/18/2003US20030175273 Monoclonal antibodies which preferentially bind to chemokine receptors, used for immunotherapy, as antiinflammatory, aniticarcinogenic agents and for prophylaxis of respiratory system disorders or antiallergens
09/18/2003US20030175269 Light and heavy chain peptides, used as antagonists of CD antigen or membrane proteins, for prophylaxis of autoimmune diseases
09/18/2003US20030175261 Captopril; hyaluronidases; phospholipases
09/18/2003US20030175256 Allografts comprising undifferentiated fetal skin cells integrated within collagen matrix
09/18/2003US20030175252 Therapeutic compounds for ovarian cancer
09/18/2003US20030175249 For labeling/activating antigen presenting cells; chaperone proteins
09/18/2003US20030175247 For activating lymphocytes (CD-8 antigens) in response to metastatic cancer; tumor associated antigens; major histocompatibility complex; cryopreservation; prostate specific antigen
09/18/2003US20030175245 Replication deficient adenoviral TNF vector
09/18/2003US20030175244 Capsid-modified recombinant adenovirus and methods of use
09/18/2003US20030175209 Image diagnosis of a brain tumor, renal carcinoma; tumor treatment therapies, immunotherapy
09/18/2003US20030175206 Administering large liposomes to retend radioactive decay intermediates
09/18/2003US20030175205 Comprising a radioactive materials for detecting and/or quantifying diseases or conditions associated with cancer, infections, inflammation; a 2-propane carboxylic ester with a attached phosphatidic acid group
09/18/2003CA2813780A1 Genetic products differentially expressed in tumors and use thereof
09/18/2003CA2671976A1 Methods of inducing terminal differentiation
09/18/2003CA2518695A1 Downregulation of ca 125 tumor antigen and uses thereof
09/18/2003CA2518586A1 Fuel additive
09/18/2003CA2480001A1 Chain oligolactic acid thioester
09/18/2003CA2478996A1 New composition including a pigment assembly comprising a mica core
09/18/2003CA2478942A1 An optically active pyridine derivative and a medicament containing the same
09/18/2003CA2478921A1 Novel chalcone derivatives and uses thereof
09/18/2003CA2478846A1 Use of mixtures of lipopeptides for vaccine production
09/18/2003CA2478827A1 Remedies for sex hormone-dependent disease
09/18/2003CA2478706A1 Oxo-azabicyclic compounds
09/18/2003CA2478701A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino) pyrimidine with cdk inhibitory activity
09/18/2003CA2478684A1 Dispersed solid-containing complex carbohydrate
09/18/2003CA2478604A1 Cancer-linked gene as target for chemotherapy
09/18/2003CA2478593A1 Cancer-linked gene as target for chemotherapy
09/18/2003CA2478592A1 Genomic screen for epigenetically silenced genes associated with cancer
09/18/2003CA2478522A1 Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis
09/18/2003CA2478510A1 Genomic screen for epigenetically silenced tumor suppressor genes
09/18/2003CA2478413A1 Genetic products differentially expressed in tumors and use thereof
09/18/2003CA2478346A1 Specific ab1'-antibodies against tumour-associated antigen ca 125
09/18/2003CA2478342A1 Heterocyclic amide derivatives for the treatment of diabetes and other diseases
09/18/2003CA2478338A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers
09/18/2003CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
09/18/2003CA2478276A1 Azepane derivatives and their use as atk1 inhibitors
09/18/2003CA2478239A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
09/18/2003CA2478177A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
09/18/2003CA2478169A1 Human antibodies specific to kdr and uses thereof
09/18/2003CA2478116A1 Neoplasm specific antibodies and uses thereof
09/18/2003CA2478087A1 Microtubule stabilizing compounds
09/18/2003CA2478065A1 Macrocyclic compounds useful as pharmaceuticals
09/18/2003CA2477973A1 Methods for alzheimer's disease treatment and cognitive enhancement
09/18/2003CA2477780A1 Methods of enhancing immune induction involving mda-7
09/18/2003CA2476938A1 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43
09/18/2003CA2476767A1 Use of the mal protein as a tumour marker
09/18/2003CA2474771A1 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
09/18/2003CA2423259A1 New compounds derived from quinazoline, the process for preparing them, and the pharmaceutical compositions containing them
09/17/2003EP1344826A1 Materials comprising and methods of preparation and use for ribosome - inactivating proteins
09/17/2003EP1344823A1 Novel g protein-coupled receptor proteins and dnas thereof
09/17/2003EP1344777A1 Imidazole derivatives, process for their preparation and their use
09/17/2003EP1344064A2 Compositions and methods relating to prostate specific genes and proteins
09/17/2003EP1343912A2 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
09/17/2003EP1343900A2 Oxidoreductases
09/17/2003EP1343893A1 Production of stilbenes in transgenic plants and the method of producing thereof
09/17/2003EP1343890A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
09/17/2003EP1343886A2 Compositions and methods for the therapy and diagnosis of lung cancer
09/17/2003EP1343884A2 Jfy1 protein induces rapid apoptosis
09/17/2003EP1343876A2 Modulators of activity of g-protein-coupled receptor kinases
09/17/2003EP1343871A2 Isolation and use of solid tumor stem cells
09/17/2003EP1343826A1 Polysaccharide compound having immune stimulating activity
09/17/2003EP1343822A2 Means for the diagnosis and therapy of ctcl
09/17/2003EP1343819A1 Hla-a2.1 binding peptides and their uses
09/17/2003EP1343817A2 Novel treatment
09/17/2003EP1343813A1 Novel compounds
09/17/2003EP1343803A2 2-substituted estrogens as antiangiogenic agents
09/17/2003EP1343789A1 Tricyclic derivatives of indole with antiangiogenic activity
09/17/2003EP1343784A2 Urea substituted imidazoquinoline ethers
09/17/2003EP1343783A2 Substituted imidazopyridines
09/17/2003EP1343782A1 Pyrimidineamines as angiogenesis modulators
09/17/2003EP1343781A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
09/17/2003EP1343779A2 Novel compounds
09/17/2003EP1343769A1 Benzoylpyridazines
09/17/2003EP1343767A2 Synthesis of pancratistatin
09/17/2003EP1343764A1 Urea and urethane derivatives as integrin inhibitors
09/17/2003EP1343759A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands
09/17/2003EP1343757A1 Indole derivatives
09/17/2003EP1343534A2 Treatment of cancer with positron-emitting radiopharmaceuticals
09/17/2003EP1343531A2 Conjugates of antibodies and anticancer drugs
09/17/2003EP1343529A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
09/17/2003EP1343527A2 Adjuvant combination formulations
1 ... 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 ... 2211